Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection

Surgery (United States)

Volumn 161, Issue 2, 2017, Pages 332-340

  Passot, Guillaume ^a   Denbo, Jason W ^a   Yamashita, Suguru ^a   Kopetz, Scott E ^a   Chun, Yun S ^a   Maru, Dipen ^a   Overman, Michael J ^a   Brudvik, Kristoffer Watten ^a   Conrad, Claudius ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; OXALIPLATIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ARTICLE; CODON; COLORECTAL LIVER METASTASIS; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RAT SARCOMA VIRAL ONCOGENE HOMOLOGUE GENE; RISK FACTOR; ANALYSIS OF VARIANCE; COHORT ANALYSIS; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FACTUAL DATABASE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SECONDARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ANALYSIS OF VARIANCE; COHORT STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85009973174     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2016.07.032     Document Type: Article

References (35)

1. 1 Manfredi, S., Lepage, C., Hatem, C., Coatmeur, O., Faivre, J., Bouvier, A.M., Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244 (2006), 254–259.
2. 2 Kopetz, S., Chang, G.J., Overman, M.J., Eng, C., Sargent, D.J., Larson, D.W., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27 (2009), 3677–3683.
3. 3 Cucchetti, A., Ferrero, A., Cescon, M., Donadon, M., Russolillo, N., Ercolani, G., et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 22 (2015), 1908–1914.
4. 4 Fong, Y., Fortner, J., Sun, R.L., Brennan, M.F., Blumgart, L.H., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999), 309–318.
5. 5 Nordlinger, B., Guiguet, M., Vaillant, J.C., Balladur, P., Boudjema, K., Bachellier, P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77 (1996), 1254–1262.
6. 6 Rubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A.D., Andres, A., Audard, V., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18 (2007), 299–304.
7. 7 Blazer, D.G. 3rd, Kishi, Y., Maru, D.M., Kopetz, S., Chun, Y.S., Overman, M.J., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26 (2008), 5344–5351.
8. 8 Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634.
9. 9 Van Cutsem, E., Kohne, C.H., Hitre, E., Zaluski, J., Chang Chien, C.R., Makhson, A., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
10. 10 Douillard, J.Y., Oliner, K.S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
11. 11 Kawamoto, Y., Tsuchihara, K., Yoshino, T., Ogasawara, N., Kojima, M., Takahashi, M., et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer 107 (2012), 340–344.
12. 12 Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17 (2010), 1429–1434.
13. 13 Knijn, N., Mekenkamp, L.J., Klomp, M., Vink-Börger, M.E., Tol, J., Teerenstra, S., et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104 (2011), 1020–1026.
14. 14 Brudvik, K.W., Kopetz, S.E., Li, L., Conrad, C., Aloia, T.A., Vauthey, J.N., Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102 (2015), 1175–1183.
15. 15 Karagkounis, G., Torbenson, M.S., Daniel, H.D., Azad, N.S., Diaz, L.A. Jr., Donehower, R.C., et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119 (2013), 4137–4144.
16. 16 Margonis, G.A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M.A., Pawlik, T.M., Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 22 (2015), 4158–4165.
17. 17 Shindoh, J., Tzeng, C.W., Aloia, T.A., Curley, S.A., Zimmitti, G., Wei, S.H., et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg 100 (2013), 1777–1783.
18. 18 Kopetz, S., Vauthey, J.N., Perioperative chemotherapy for resectable hepatic metastases. Lancet 371 (2008), 963–965.
19. 19 Charnsangavej, C., Clary, B., Fong, Y., Grothey, A., Pawlik, T.M., Choti, M.A., Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13 (2006), 1261–1268.
20. 20 Shindoh, J., Tzeng, C.W., Aloia, T.A., Curley, S.A., Huang, S.Y., Mahvash, A., et al. Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: an institutional experience of 358 patients. J Gastrointest Surg 18 (2014), 45–51.
21. 21 Brouquet, A., Abdalla, E.K., Kopetz, S., Garrett, C.R., Overman, M.J., Eng, C., et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29 (2011), 1083–1090.
22. 22 Pawlik, T.M., Scoggins, C.R., Zorzi, D., Abdalla, E.K., Andres, A., Eng, C., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241 (2005), 715–722.
23. 23 Passot, G., Chun, Y.S., Kopetz, S.E., Zorzi, D., Brudvik, K.W., Kim, B.J., et al. Predictors of safety and efficacy of two stage hepatectomy for bilateral colorectal liver metastases. J Am Coll Surg 223 (2016), 99–108.
24. 24 Parkin, E., O'Reilly, D.A., Adam, R., Kaiser, G.M., Laurent, C., Elias, D., et al. Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy. Eur J Surg Oncol 40 (2014), 1436–1444.
25. 25 Kanas, G.P., Taylor, A., Primrose, J.N., Langeberg, W.J., Kelsh, M.A., Mowat, F.S., et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4 (2012), 283–301.
26. 26 Vincenzi, B., Cremolini, C., Sartore-Bianchi, A., Russo, A., Mannavola, F., Perrone, G., et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 6 (2015), 31604–31612.
27. 27 Goéré, D., Benhaim, L., Bonnet, S., Malka, D., Faron, M., Elias, D., et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 257 (2013), 114–120.
28. 28 Power, D.G., Kemeny, N.E., Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol 28 (2010), 2300–2309.
29. 29 Margonis, G.A., Kim, Y., Spolverato, G., Ejaz, A., Gupta, R., Cosgrove, D., et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg 150 (2015), 722–729.
30. 30 Allegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (2009), 2091–2096.
31. 31 De Roock, W., Jonker, D.J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304 (2010), 1812–1820.
32. 32 Peeters, M., Douillard, J.Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31 (2013), 759–765.
33. 33 Tejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., Van Cutsem, E., Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30 (2012), 3570–3577.
34. 34 Zakaria, S., Donohue, J.H., Que, F.G., Farnell, M.B., Schleck, C.D., Ilstrup, D.M., et al. Hepatic resection for colorectal metastases: value for risk scoring systems?. Ann Surg 246 (2007), 183–191.
35. 35 Adam, R., Pascal, G., Castaing, D., Azoulay, D., Delvart, V., Paule, B., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004), 1052–1061.